No genetic evidence for an association of apolipoprotein A-I with cardiovascular outcomes at different LDL cholesterol levels: drug-target Mendelian randomization analyses.

Abstract excerpt

BACKGROUND AND AIMS: Exploratory post-hoc analyses of the AEGIS-II trial suggested that the efficacy of CSL112 (apolipoprotein A-I infusion) may be greater in patients with high baseline LDL-C. This genetic study aimed to assess whether LDL-C levels modify the effect of apoA-I on cardiovascular outcomes. METHODS: We conducted drug-target Mendelian randomization analyses using data from 339,210 UK Biobank...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Apolipoprotein A-I
• Share to Cardiovascular Diseases